p21 (CDKN1A / WAF1 / CIP1)
Also known as: WAF1, CIP1, SDI1, MDA-6, CDKN1A, p21WAF1/CIP1, p21Cip1, p21Waf1, Cyclin-Dependent Kinase Inhibitor 1A, RAS-p21 (distinct oncogenic GTPase — see no_data_topics note)
Cyclin-Dependent Kinase Inhibitor (CKI), CIP/KIP family; intrinsically disordered protein (IDP)
What it is
p21 is a naturally occurring protein that controls cell division and acts as a tumor suppressor; researchers are studying ways to restore or target it in bladder cancer, melanoma, and other cancers. It works by putting the brakes on uncontrolled cell growth. Not approved as a therapeutic; studied in early cancer research models.
The scientific side
p21 (CDKN1A/WAF1/CIP1) is a small, intrinsically disordered protein and broad-specificity inhibitor of cyclin-dependent kinase (CDK) complexes. It was originally identified as a transcriptional target of the tumor suppressor p53 and a primary mediator of p53-dependent cell-cycle arrest in response to DNA damage. By suppressing CDK activity, nuclear p21 arrests the cell cycle at G1 and G2 phases and inhibits PCNA-dependent DNA replication. p21 also possesses CDK-independent functions: residual S-phase p21 controls DNA replication speed and origin firing via direct displacement of partners from chromatin-bound PCNA. p21 protein levels are controlled at multiple layers — transcriptionally (by p53-dependent and p53-independent mechanisms including epigenetic silencing via histone methylation/deacetylation), post-transcriptionally (mRNA stability regulated by RNA-binding proteins such as AUF1 and CUGBP1, and by competing circRNAs such as circPCNX), and post-translationally (phosphorylation by kinases including AKT and CDK2; proteasomal degradation via both ubiquitin-dependent N-terminal ubiquitinylation and ubiquitin-independent 20S proteasomal degradation mediated by the PSMA3 Trapper through the RRLIF degron). Subcellular localization critically determines p21's function: nuclear p21 is generally tumor-suppressive (cell cycle arrest, senescence, genomic stability), while cytoplasmic p21 is associated with pro-oncogenic effects including inhibition of apoptosis, promotion of cancer stem cell properties via NFκB activation, and chemoresistance. Phosphorylation events (notably at T145 by AKT) drive cytoplasmic translocation. p21 also participates in cellular responses to oxidative stress through conserved cysteine-switch redox-sensing mechanisms in its Kinase Inhibitory Domain (KID), enabling direct sensing of reactive oxygen species (ROS). Beyond cell cycle control, p21 participates in regulation of autophagy, apoptosis, senescence, macrophage activation, osteoblast differentiation, metabolic processes, cardiac function, melanogenesis, and inflammatory responses.
Class: Cyclin-Dependent Kinase Inhibitor (CKI), CIP/KIP family; intrinsically disordered protein (IDP)
Administration & storage
- Administration
- Intravesical administration of p21 mRNA-loaded lipid nanoparticles (p21-LNP) in orthotopic mouse bladder cancer model (PMID: 42144924)Intraarticular injection of lentiviral shRNA targeting p21 in mouse cartilage defect model (PMID: 42007882)Intraperitoneal injection of LPS (5 mg/kg) to induce sepsis model in which p21 role was studied — not p21 itself (PMID: 32694519)
- Storage
- No abstracts in the reviewed set describe storage conditions for p21 protein or p21-based therapeutic preparations.
- Cautions
- p21 (CDKN1A) has a well-documented dual role as both tumor suppressor and oncogene depending on subcellular localization and cellular context — therapeutic targeting without precise localization control carries risk of paradoxical pro-tumorigenic effects (PMID: 42201575, PMID: 11880176).,Cytoplasmic p21 promotes cancer stem cell properties and chemoresistance via NFκB activation and AKT-p21 phosphorylation axis; increasing p21 expression without controlling its localization may worsen outcomes in certain cancers (PMID: 41178462, PMID: 41462552).,In an in vivo mouse cartilage repair model, lentiviral delivery of p21 shRNA resulted in minimal but detectable hepatic off-target transduction, which increased in injured animals; morphological hepatotoxicity was not observed, but off-target effects require monitoring.,p21-/- iPSCs formed tumors post-transplantation in the absence of iCasp9 activation in a mouse model; robust safety mechanisms (e.g., suicide gene systems) are required when using p21-knockout stem cells therapeutically.,No human pharmacokinetic data for exogenous p21 protein or p21 mRNA administration are reported in the reviewed literature — extrapolation of preclinical findings to clinical use is not supported by available evidence.,IMPORTANT DISAMBIGUATION: 'RAS-p21' (the oncogenic GTPase encoded by RAS genes) is a completely different protein from CDKN1A/WAF1/CIP1 p21. FDA-approved agents targeting RAS-p21 (sotorasib, adagrasib) do not act on CDKN1A p21. Confusing these two proteins in a clinical context could have serious consequences.
Legal & regulatory status
Not stated in reviewed literature — requires manual verification. NOTE: Two FDA-approved small molecules targeting the distinct oncogenic GTPase RAS-p21 (AMG510/sotorasib and MRTX849/adagrasib) are mentioned in PMID…
Not stated in reviewed literature — requires manual verification.
Not stated in reviewed literature — requires manual verification.
What it's studied for
- Cell cycle arrest and tumor suppression (general cancer biology) Mixed
- Reviews the dichotomous role of p21 in oncogenesis: nuclear p21 is anti-cancerogenic via CDK inhibition and cell cycle arrest; cytoplasmic p21 is pro-cancerogenic. Post-translational modifications (mainly phosphorylations) govern intracellular localization and ultimate cell fate. PMID 42201575 Maheshwari & Harioudh, Mol Biol Rep 2026
- Transcriptional repression of p21 by oncogenes (e.g., c-Myc) promotes cell growth and tumorigenesis; p21 repression can also sensitize tumor cells to apoptosis by anticancer drugs. PMID 15899785 Gartel & Radhakrishnan, Cancer Res 2005
- p21 exhibits both tumor suppressor and oncogenic functions; p21 knockout mouse studies and human cancer expression patterns support dual role. Oncogenic functions include endoreduplication, apoptosis inhibition, and stimulation of secreted mitogenic/anti-apoptotic factors. PMID 11880176 Roninson, Cancer Lett 2002
- p21 (WAF1/CIP1/SDI1/MDA-6) induces G1 arrest and blocks S phase entry by inactivating CDKs and inhibiting PCNA. Overexpression suppresses tumor growth in vitro and in vivo. PMID 8931660 Gartel et al., Proc Soc Exp Biol Med 1996
- Reviews multiple functions of p21 in cell cycle regulation, apoptosis, and gene transcription after DNA damage; discusses p53-dependent and p53-independent induction mechanisms. PMID 27156098 Karimian et al., DNA Repair 2016
- Bladder cancer — tumor suppressor replacement therapy (mRNA-LNP intravesical delivery) Animal studies only
- p21 mRNA encapsulated in lipid nanoparticles (p21-LNP) delivered intravesically suppressed tumor growth in an orthotopic mouse bladder cancer model, restored p21 expression in bladder tissues, and preserved urothelial architecture without obvious adverse effects. In vitro, synthetic p21 mRNA suppressed proliferation, v PMID 42144924 Zeng et al., FASEB J 2026
- Colorectal cancer — cytoplasmic p21 as driver of cancer stem cell properties and metastasis Mixed
- Cytoplasmic p21 (phosphomimetic T145D) enhanced spheroid formation, CD133 expression, and stemness factors (Oct3/4, Nanog, Sox2) in CRC cells via NFκB activation. Cytoplasmic p21 correlated with advanced stage and metastasis in CRC patients; NFκB targets BCL-xL and COX2 were identified as downstream effectors. PMID 41178462 Maiuthed et al., Mol Oncol 2026
- Melanoma — chemoresistance and prognosis marker Human observational
- Increased p21 gene and protein expression predicts poor prognosis in human melanoma. Higher cytoplasmic p21 and AKT-mediated phosphorylation are associated with resistance to dacarbazine. PI3K inhibition diminished p21 phosphorylation; p21 downregulation sensitized cells to chemotherapy. PMID 41462552 Colaneri et al., Sci Rep 2025
- Pancreatic endocrine tumor — biomarker for liver metastasis prediction Human observational
- High p21 IHC score (Allred ≥4) was strongly associated with liver metastases in primary pancreatic endocrine tumors (93% sensitivity, 68% specificity, 78% predictive accuracy). p21 IHC outperformed conventional clinico-pathological criteria. PMID 37889062 Nasir et al., Cancer Genomics Proteomics 2023
- Ovarian cancer — therapeutic target (p21 inhibition) and senescence regulation Mixed
- High p21 expression found in ~50% of ovarian clear-cell carcinoma patients. Treatment with the p21 inhibitor UC2288 attenuated proliferation and induced apoptosis in two CCC cell lines, more prominently in the high-p21-expressing JHOC-9 line. PMID 32988887 Minagawa et al., Anticancer Res 2020
- PTEN promoted senescence of SKOV3 ovarian cancer cells by increasing TRIM39 expression, which stabilized p21 and decreased its degradation. TRIM39 overexpression upregulated p21 and increased senescent cell numbers. PMID 34643308 Ke et al., Cell Biol Int 2022
- In 316 epithelial ovarian cancers, low p21/WAF1 expression correlated with high tumor grade, advanced stage, residual tumor, and poor overall survival. p21-/p53+ phenotype predicted significantly worse outcomes. PMID 10206307 Anttila et al., Br J Cancer 1999
- Breast cancer — prognostic marker and therapeutic target Mixed
- Reviews paradoxical role of p21 in breast cancer: nuclear p21 acts as tumor suppressor/cell cycle inhibitor; cytoplasmic p21 is anti-apoptotic. Subcellular localization impacts clinicopathological factors, prognosis, and chemotherapy responsiveness. PMID 30255294 Zohny et al., Breast Cancer 2019
- In 91 breast cancer patients, p21 status inversely correlated with p53; highly p21-positive patients had significantly improved overall survival (p=0.020). p21+/p53- patients had good survival; p21-/p53+ patients did poorly (p=0.008). p21 status did not predict response to endocrine therapy. PMID 10398154 McClelland et al., J Pathol 1999
- USP30-AS1 lncRNA suppresses p21 (CDKN1A) in breast cancer via cytoplasmic HnRNPF/p21 mRNA destabilization and nuclear EZH2/c-Myc/p21 transcriptional repression axes; knockdown of USP30-AS1 upregulates p21 and suppresses tumor growth. PMID 41492473 Jiang et al., Genes Dis 2026
- Esophageal squamous cell carcinoma — radiation response and lincRNA-p21 tumor suppression Mixed
- All four esophageal SCC cell lines increased p21 expression in response to radiation (3–24 Gy) independent of p53 mutation status, with basal p21 levels of 3.2–7.8 ng/mL increasing to 6.4–16.8 ng/mL at 3 Gy. PMID 9698513 Rigberg et al., J Surg Res 1998
- LincRNA-P21 knockdown increased cell viability, growth, and migration in ESCC cells by upregulating CDH5 via YTHDC1; lincRNA-P21 acts as a tumor suppressor in ESCC. PMID 37766459 Wang et al., Acta Biochim Biophys Sin 2023
- Hepatocellular carcinoma — lincRNA-p21 as tumor suppressor and therapeutic target Animal studies only
- LincRNA-p21 was downregulated in hepatocellular carcinoma tissues; low expression correlated with high disease stage and poor survival. Overexpression inhibited HepG2 growth in vivo and contributed to sorafenib-induced growth regression via ER stress-mediated apoptosis. PMID 26305675 Yang et al., Oncotarget 2015
- Non-small cell lung cancer — lincRNA-p21 and angiogenesis regulation/prognosis Human observational
- High lincRNA-p21 expression associated with poor cancer-specific survival in NSCLC adenocarcinoma patients (CSS p<0.001). LincRNA-p21 inhibition reduced angiogenic gene expression and VEGFA secretion in vitro; high lincRNA-p21 tumors had higher microvascular density. PMID 27496652 Castellano et al., J Thorac Oncol 2016
- Cancer radiotherapy — multiple cellular roles Mixed
- Reviews p21's roles in radiation response: cell cycle arrest, apoptosis, DNA repair, senescence, and autophagy. Discusses feasibility, barriers, and risks of using p21 as a biomarker and therapeutic target in radiotherapy. PMID 33547489 Kuang et al., J Cancer Res Clin Oncol 2021
- p21-deficient cancer and normal cells showed higher γH2AX induction (DNA damage marker) during S-phase in response to Wee1 inhibitor MK1775; p21 deficiency increased MK1775-induced cell death and sensitized cells to combined Wee1 + CHK1 inhibition or ionizing radiation. PMID 30902882 Hauge et al., Cell Cycle 2019
- Osteoarthritis / cartilage repair — p21 as regulator and therapeutic target Animal studies only
- P21 expression was significantly reduced in OA cartilage from human cohorts and animal models, negatively correlating with disease severity. DHA@HAMA nanoparticles restored P21 levels, alleviated oxidative stress via P21-mediated PI3K/AKT signaling, promoted anabolic markers, and suppressed catabolic markers, mitigatin PMID 42192449 Fang et al., J Nanobiotechnol 2026
- Lentiviral shRNA achieving ~80% p21 mRNA knockdown significantly improved cartilage repair in both immunocompromised and immunocompetent mouse models. Tissue cytometry showed 90% transduction efficiency; Spearman correlation demonstrated significant negative correlation between p21 expression and repair outcomes. Minim PMID 42007882 Larijani et al., FASEB J 2026
- p21-/- iPSCs engineered with iCasp9 showed comparable cartilage regeneration to wildtype iPSCs; iCasp9 activation (AP20187) eliminated tumors post-transplantation in a mouse cartilage injury model, supporting safety of this approach. PMID 41259786 Larijani et al., Stem Cells Transl Med 2025
- Bone regeneration — role of p21/E2f1 axis Animal studies only
- Loss of p21 increased trabecular bone formation post-injury in C57BL/6 mice; loss of E2f1 increased cortical bone but negated pro-osteogenic impacts of p21 loss when both were knocked out simultaneously, reducing osteoblast, osteoclast, and chondrocyte numbers at injury site. PMID 38643416 Premnath et al., Calcif Tissue Int 2024
- p21 acts as a brake on osteoblast proliferation and differentiation; p21-null osteoblasts differentiated faster and were more susceptible to BMP-2-induced differentiation. Transient p21 overexpression from adenovirus vector delayed differentiation onset. PMID 12733720 Bellosta et al., J Bone Miner Res 2003
- Diabetes and metabolic disorders — p21 as regulator of glucose homeostasis and insulin resistance Mixed
- Reviews evidence that p21 is directly and indirectly linked to metabolic processes including pancreatic function, glucose homeostasis, and insulin resistance. Summarizes therapies targeting p21 to alleviate metabolic disorders. PMID 39684919 Elmitwalli et al., Int J Mol Sci 2024
- Using p21-3MR mouse model, p16/p21 senescence markers showed significant spatiotemporal heterogeneity across tissues during T2D progression. Dasatinib+quercetin outperformed p21 intervention alone in reducing dual-positive senescent cells in several tissues. PMID 41099311 Yan et al., Cell Biochem Funct 2025
- Systemic lupus erythematosus — genetic association Human observational
- In a case-control study of 516 SLE patients and 693 controls, p21US A allele (OR=0.23) and p21-1022 A allele (OR=1.95) were significantly associated with SLE. p21US GA genotype was associated with arthritis in SLE patients; differential p21 mRNA expressions observed among genotypes. PMID 16837471 Kong et al., Rheumatology 2007
- Cellular senescence monitoring and elimination (p21 as senescence marker) Animal studies only
- p21-ATD transgenic mouse model enabled in vivo tracing and elimination of p21-expressing senescent cells. Eliminating p21+ cells in aged mice recovered biological functions; in liver injury model, eliminating p21+ hepatocytes promoted engraftment of grafted hepatocytes and facilitated liver repopulation. PMID 38582962 Chen et al., Mol Ther 2024
- Sepsis/cardiac dysfunction — cardioprotective role of p21 Animal studies only
- In LPS-induced mouse sepsis model (5 mg/kg LPS i.p.), p21 knockout aggravated cardiac dysfunction, increased inflammatory response, oxidative stress, and mitochondrial damage. p21 overexpression attenuated TNFα and promoted SOD2; p21 regulated autophagy via LC3B interaction. Rapamycin partially rescued cardiac deterior PMID 32694519 Huang et al., Cell Death Dis 2020
- Macrophage activation regulation / inflammatory diseases Animal studies only
- p21 acts as a negative regulator of macrophage activation, inhibiting LPS-dependent induction of TNF-alpha and IL-1beta through NF-kappaB activity. p21-/- mice are more susceptible to septic shock. PMID 19283709 Lloberas & Celada, Eur J Immunol 2009
- RAS-p21 oncogenic GTPase — peptide-based inhibition (distinct protein from CDKN1A p21) Mixed
- Reviews peptides (PNC-1, PNC-2, PNC-7) and small molecules targeting mutant oncogenic RAS-p21 GTPase (distinct from CDKN1A p21). Notes FDA approval of AMG510 (sotorasib) and MRTX849 (adagrasib) for RAS-p21 G12C mutant-driven cancers. IMPORTANT: RAS-p21 is a GTPase encoded by the RAS gene family — a completely different PMID 36831007 Pincus et al., Biomedicines 2023
- Bladder cancer — BCG therapy response mediated by p21 expression In vitro only
- p21 overexpression in T24 urothelial carcinoma cells caused G0/G1 arrest, decreased basal caspase-3 activity, reversed camptothecin-induced caspase-3 activity, and was required for BCG's direct cytotoxic effect. p21 was both sufficient and necessary for the full antiapoptotic effect of BCG. PMID 19450997 See et al., Urol Oncol 2010
- Melanogenesis — p21 maintains MITF-driven melanogenic signaling Animal studies only
- CRISPR/Cas9-mediated p21 knockout in B16F1 melanoma cells reduced expression of p21, p53, CDK2, Cyclin D, Cyclin E, MITF, TRP-1, TRP-2, TYR, and p-ERK, indicating p21 is essential for maintaining MITF-driven melanogenic signaling. Knockout also reduced melanin synthesis and collagen production. PMID 42214793 Kim & Kim, J Biotechnol 2026
- Chronic hepatitis B / liver fibrosis — lincRNA-p21 as serum biomarker Human observational
- Serum lincRNA-p21 levels were lower in 417 CHB patients vs. 363 healthy controls and negatively correlated with liver fibrosis stage. ROC AUC=0.854 with 100% sensitivity and 70% specificity for discriminating liver fibrosis from healthy controls. PMID 28107589 Yu et al., J Viral Hepat 2017
- Exercise and CNS aging — context-dependent modulation of p21 signaling Animal studies only
- Review of preclinical evidence: sustained physiological exercise reduced hippocampal/cortical p21-associated signatures in models of metabolic distress, aging, and amyloid pathology; acute treadmill exercise transiently increased hippocampal Cdkn1a; excessive swimming produced sustained hippocampal p53-p21 activation w PMID 42632465 Sun et al., Ageing Res Rev 2026
Protocol
1 mg subcutaneous injection, once daily. Cycle: 20 days on, 20 days off (cycled).
About these dose ranges
Dose ranges below reflect commonly reported community protocols. Where published research cites a specific dose, the PMID is linked. Doses without citations are not clinical recommendations — they reflect what practitioners and researchers commonly report using.
Community-reported dosing
| Route | Dose | Frequency / Duration | Population / context | Source tier |
|---|---|---|---|---|
| intraperitoneal (LPS, not p21 protein) | 5 mg/kg LPS intraperitoneally (to induce sepsis model in which p21 role was studied; p21 itself was not administered as an exogenous agent) | 6, 24, or 48 hours post-LPS | animal | Research PMID 32694519 |
| intravesical (in vivo mouse model) | p21 mRNA encapsulated in lipid nanoparticles (p21-LNP); specific mg/kg dose not stated in abstract | Repeated intravesical administrations in orthotopic mouse model (exact schedule not stated in abstract) | animal | Research PMID 42144924 |
| intraarticular injection | Lentiviral shRNA targeting p21 (intraarticular injection); specific viral titer/dose not stated in abstract | Not stated in abstract | animal | Research PMID 42007882 |
| in vitro (radiation exposure) | Radiation doses of 3 to 24 Gy applied to esophageal SCC cell lines; p21 protein measured by ELISA (basal: 3.2–7.8 ng/mL; post-3 Gy: 6.4–16.8 ng/mL) | Not stated | in_vitro | Research PMID 9698513 |
| in vitro (cell line treatment) | UC2288 (p21 inhibitor); specific dose not stated in abstract | Not stated in abstract | in_vitro | Research PMID 32988887 |
| subcutaneous injection | 1 mg | once daily · 20 days on, 20 days off (cycled) | biohackers and longevity-focused individuals seeking cell cycle regulation and anti-aging effects | [Community] |
| subcutaneous injection | 1 mg | once daily · 30 days continuous | biohackers and anti-aging enthusiasts running a full continuous cycle before reassessing | [Community] |
| subcutaneous injection | 500 mcg | once daily · 20 days on, 20 days off (cycled) | biohackers who prefer a lower starting dose for first-time use of P21 | [Community] |
| subcutaneous injection | 1 mg | once daily · 20 days on, 20 days off, repeated for 2–3 cycles | experienced biohackers pursuing extended longevity protocols | [Community] |
| subcutaneous injection | 1 mg | once daily · 20 days on, 20 days off | biohackers stacking P21 with Epitalon for synergistic longevity effects | [Community] |
All studies (37)
- PMID 16837471 Human observational
Systemic lupus erythematosus — genetic association - PMID 27496652 Human observational
Non-small cell lung cancer — lincRNA-p21 and angiogenesis regulation/prognosis - PMID 28107589 Human observational
Chronic hepatitis B / liver fibrosis — lincRNA-p21 as serum biomarker - PMID 37889062 Human observational
Pancreatic endocrine tumor — biomarker for liver metastasis prediction - PMID 41462552 Human observational
Melanoma — chemoresistance and prognosis marker - PMID 8931660 Mixed
Cell cycle arrest and tumor suppression (general cancer biology) - PMID 9698513 Mixed
Esophageal squamous cell carcinoma — radiation response and lincRNA-p21 tumor suppression - PMID 10206307 Mixed
Ovarian cancer — therapeutic target (p21 inhibition) and senescence regulation - PMID 10398154 Mixed
Breast cancer — prognostic marker and therapeutic target - PMID 11880176 Mixed
Cell cycle arrest and tumor suppression (general cancer biology) - PMID 15899785 Mixed
Cell cycle arrest and tumor suppression (general cancer biology) - PMID 27156098 Mixed
Cell cycle arrest and tumor suppression (general cancer biology) - PMID 30255294 Mixed
Breast cancer — prognostic marker and therapeutic target - PMID 30902882 Mixed
Cancer radiotherapy — multiple cellular roles - PMID 32988887 Mixed
Ovarian cancer — therapeutic target (p21 inhibition) and senescence regulation - PMID 33547489 Mixed
Cancer radiotherapy — multiple cellular roles - PMID 34643308 Mixed
Ovarian cancer — therapeutic target (p21 inhibition) and senescence regulation - PMID 36831007 Mixed
RAS-p21 oncogenic GTPase — peptide-based inhibition (distinct protein from CDKN1A p21) - PMID 37766459 Mixed
Esophageal squamous cell carcinoma — radiation response and lincRNA-p21 tumor suppression - PMID 39684919 Mixed
Diabetes and metabolic disorders — p21 as regulator of glucose homeostasis and insulin resistance - PMID 41099311 Mixed
Diabetes and metabolic disorders — p21 as regulator of glucose homeostasis and insulin resistance - PMID 41178462 Mixed
Colorectal cancer — cytoplasmic p21 as driver of cancer stem cell properties and metastasis - PMID 41492473 Mixed
Breast cancer — prognostic marker and therapeutic target - PMID 42201575 Mixed
Cell cycle arrest and tumor suppression (general cancer biology) - PMID 12733720 Animal studies only
Bone regeneration — role of p21/E2f1 axis - PMID 19283709 Animal studies only
Macrophage activation regulation / inflammatory diseases - PMID 19450997 In vitro only
Bladder cancer — BCG therapy response mediated by p21 expression - PMID 26305675 Animal studies only
Hepatocellular carcinoma — lincRNA-p21 as tumor suppressor and therapeutic target - PMID 32694519 Animal studies only
Sepsis/cardiac dysfunction — cardioprotective role of p21 - PMID 38582962 Animal studies only
Cellular senescence monitoring and elimination (p21 as senescence marker) - PMID 38643416 Animal studies only
Bone regeneration — role of p21/E2f1 axis - PMID 41259786 Animal studies only
Osteoarthritis / cartilage repair — p21 as regulator and therapeutic target - PMID 42007882 Animal studies only
Osteoarthritis / cartilage repair — p21 as regulator and therapeutic target - PMID 42144924 Animal studies only
Bladder cancer — tumor suppressor replacement therapy (mRNA-LNP intravesical delivery) - PMID 42192449 Animal studies only
Osteoarthritis / cartilage repair — p21 as regulator and therapeutic target - PMID 42214793 Animal studies only
Melanogenesis — p21 maintains MITF-driven melanogenic signaling - PMID 42632465 Animal studies only
Exercise and CNS aging — context-dependent modulation of p21 signaling